Multiple Sclerosis and Epstein-Barr Virus

JAMA

Volumn 289, Issue 12, 2003, Pages 1533-1536

  Levin, Lynn I ^a   Munger, Kassandra L ^d   Rubertone, Mark V ^b   Peck, Charles A ^c   Lennette, Evelyne T ^e   Spiegelman, Donna ^d   Ascherio, Alberto ^d  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b Army Medical Surveillance Activity   (United States)

^c US Army Physical Disability Agency   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e Virolab Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; EARLY ANTIGEN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; VIRUS ANTIBODY; VIRUS CAPSID ANTIGEN; CAPSID PROTEIN; EPSTEIN BARR VIRAL CAPSID ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS EARLY ANTIGEN; EPSTEIN BARR VIRUS EARLY ANTIGEN DIFFUSE COMPONENT; EPSTEIN-BARR VIRAL CAPSID ANTIGEN; EPSTEIN-BARR VIRUS EARLY ANTIGEN; EPSTEIN-BARR VIRUS EARLY ANTIGEN DIFFUSE COMPONENT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; VIRUS ANTIGEN;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS; EPSTEIN BARR VIRUS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SERUM; SOLDIER; VIRUS INFECTION; BLOOD; IMMUNOLOGY; PATHOPHYSIOLOGY; RETRACTED ARTICLE; VIROLOGY;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CASE-CONTROL STUDIES; CYTOMEGALOVIRUS; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FEMALE; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MALE; MULTIPLE SCLEROSIS;

EID: 0037467342     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.12.1533     Document Type: Article

References (19)

1. de-The G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature. 1978;274:756-761.
2. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, Pa: Lippincott-Raven; 1996:2397-2446.
3. Mueller N, Evans A, Harris NL, et al. Hodgkin's disease and Epstein-Barr virus: altered antibody pattern before diagnosis. N Engl J Med. 1989;320:689-695.
4. Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology. 1985;35:435-438.
5. Shirodaria PV, Haire M, Fleming E, et al. Viral antibody titers: comparison in patients with multiple sclerosis and rheumatoid arthritis. Arch Neurol. 1987;44: 1237-1241.
6. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA. 2001;286:3083-3088.
7. Rubertone MV, Brundage JF. The defense medical surveillance system and the Department of Defense Serum Repository: glimpses of the future of comprehensive public health surveillance. Am J Public Health. 2002;92:1900-1904.
8. Poser C, Paty D, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis. Ann Neurol. 1983; 13:227-231.
9. Henle W, Henle G, Andersson J, et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci U S A. 1987;84:570-574.
10. Lennette ET. Epstein-Barr virus. In: Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH, eds. Manual of Clinical Microbiology. 7th ed. Washington, DC: ASM Press; 1999:912-918.
11. Lennette ET, Rymo L, Yadav M, et al. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur J Cancer. 1993;29A:1584-1589.
12. Lennette E, Lennette D. Immune adherence hemagglutination. In: Specter S, Hodinka R, Young S, eds. Clinical Virology Manual. Washington, DC: ASM Press; 2000:140-145.
13. Diggle P, Liang K, Zeger S. Analysis of Longitudinal Data. Oxford, England: Clarendon Press; 1994:253.
14. Brex PA, O'Riodan JI, Miszkiel KA, et al. Multisequence MRI in clinically isolated syndromes and the eady development of MS. Neurology. 1999;53: 1184-1190.
15. Henle W, Henle G, Niederman JC, Klemola E, Haltia K. Antibodies to early antigens induced by Epstein-Barr virus in infectious mononucleosis. J Infect Dis. 1971;124:58-67.
16. Kusunoki Y, Huang H, Fukuda Y, et al. A positive correlation between the precursorfrequency of cytotoxiclymphocytes to autologous Epstein-Barr virus-transformed B cells and antibody titer level against Epstein-Barr virus-associated nuclear antigen in healthy seropositive individuals. Microbiol Immunol. 1993;37:461-469.
17. Horwitz CA, Henle W, Henle G, et al. Long-term serological follow-up of patients for Epstein-Barr virus after recovery from infectious mononucleosis. J Infect Dis. 1985;151:1150-1153.
18. de-The G. Epidemiology of Epstein-Barr virus and associated diseases in man. In: Roizman B, ed. The Herpesviruses. Vol 1. New York, NY: Plenum Press; 1982: 25-103.
19. Chien YC, Chen JY, Liu MY, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med. 2001; 345:1877-1882.